Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation

Current Eye Research

Volumn 36, Issue 8, 2011, Pages 768-773

  Maldonado, Renata Malvezzi ^a   Vianna, Raul N G ^a   Cardoso, Gilberto Perez ^a   De Magalhães, Andréia Veloso ^a   Burnier Jr , Miguel N ^b  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Anti inflammatory drugs; Diabetic macular edema; Diabetic retinopathy; Intravitreal injection; Ketorolac tromethamine

Indexed keywords

KETOROLAC; KETOROLAC TROMETAMOL;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIABETIC MACULAR EDEMA; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MACULAR THICKNESS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; SLIT LAMP; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETIC RETINOPATHY; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; KETOROLAC TROMETHAMINE; LASER COAGULATION; MACULAR EDEMA; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR; VISUAL ACUITY;

EID: 79960709309     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.585734     Document Type: Article

References (26)

1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic mac-ular edema: pathogenesis and treatment. Surv Ophthalmol. 2009 Jan-Feb;54(1):1-32.
2. Kern TS. Contributions of infammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
3. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006 Sep;55(9):2401-11. (Pubitemid 44871140)
4. Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1971-80. (Pubitemid 30354375)
5. Krady JK, Basu A, Allen CM, Xu Y, La Noue KF, Gardner TW, et al. Minocycline reduces proinfammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005 May;54(5):1559-65. (Pubitemid 40586690)
6. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008 Feb;126(2):227-32. (Pubitemid 351240852)
7. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10836-41. (Pubitemid 29442230)
8. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes. 2002 Dec;51(12):3499-504. (Pubitemid 35403456)
9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fuid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480-7 (Pubitemid 24356306)
10. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806.
11. Gardner TW, Antonetti DA. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep. 2008 Aug;8(4):263-9.
12. Margalit E, Kugler LJ, Brumm MV, Meza JL, Kompella UB, Escobar ER, et al. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci. 2006 May;47(5):2093-9. (Pubitemid 46768293)
13. Reis Ado C, Vianna RN, Reis RS, Cardoso GP. [Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation]. Arq Bras Oftalmol. 2010 Aug;73(4):338-42.
14. Komarowska I, Heilweil G, Rosenfeld PJ, Perlman I, Loewenstein A. Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits. Retina. 2009 Jan;29(1):98-105.
15. Heier J, Cheetham JK, Degryse R, Dirks MS, Caldwell DR, Silverstone DE, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular infam-mation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999 Mar;127(3):253-9. (Pubitemid 29128121)
16. Kaiser PK, Pineda R, 2nd. A study of topical nonsteroidal anti-infammatory drops and no pressure patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group. Ophthalmology. 1997 Aug;104(8):1353-9. (Pubitemid 28048736)
17. Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-in-fammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol. 2005 Nov;89(11):1420-2. (Pubitemid 41527373)
18. Kim SJ, Adams NA, Toma HS, Belair ML, Thorne JE, Green WR, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina. 2008 Apr;28(4):595-605. (Pubitemid 351589569)
19. Margalit E, Boysen JL, Zastrocky J P, Katz A. Use of intraocular ketorolac tromethamine for the treatment of chronic cystoid macular edema. Can J Ophthalmol. 2010 Aug;45(4):409-10.
20. Yamamoto Y, Komatsu T, Koura Y, Nishino K, Fukushima A, Ueno H. Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmol. 2008 Feb;43(1):42-7 (Pubitemid 351269567)
21. Effcacy of diclofenac eyedrops in preventing postoperative infammation and long-term cystoid macular edema. Italian Diclofenac Study Group. J Cataract Refract Surg. 1997 Oct;23(8):1183-9.
22. Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010 Mar;30(3):509-15.
23. Duong HV, Westfeld KC, Chalkley TH. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. J Cataract Refract Surg. 2007 Nov;33(11):1925-9. (Pubitemid 47628809)
24. Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008 Dec;2(4):689-92.
25. Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the frst twice-daily ophthalmic nonsteroidal anti-infammatory drug. Int Ophthalmol Clin. 2006 Fall;46(4):21-40. (Pubitemid 44632206)
26. Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Effcacy of bromfenac sodium ophthalmic solution in preventing cys-toid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010 Dec;88(8):896-900.